Although PD1 blockade combined with VEGF blockade and chemotherapy significantly improved PFS and OS among patients with lung adenocarcinomas with EGFR mutations [24, 31], whether or not one subtype benefits more than the other remains un-known. This evidence concerns the gene EGFR and lung adenocarcinoma.